网络药理学在中药治疗前列腺增生中的应用

The Application of Network Pharmacology in the Treatment of Benign Prostatic Hyperplasia with Traditional Chinese Medicine

摘要: 良性前列腺增生(BPH)作为中老年男性群体的常见病症，中药凭借其多靶点作用的特征，在改善临床症状及延缓疾病进展方面展现出独特优势。本文聚焦于网络药理学在中药治疗前列腺增生领域的应用现状展开探讨，该研究方法在揭示中药干预BPH的内在作用机制方面应用较为广泛。以五苓散、二至丸等中药复方为例，相关研究表明其治疗作用往往通过“多成分–多靶点–多通路”的整合调节机制得以实现。然而，当前研究仍面临靶点预测数量较多但实验验证不足、缺乏系统的研究质量评价的问题，因此需要进一步开展深入的基础实验与临床研究，以对网络药理学预测的潜在机制进行充分验证，同时引入SYRCLE、ROBIS、AMSTAR等工具提升研究结论的可靠性。

Abstract: Benign prostatic hyperplasia (BPH) is a common disorder in middle-aged and elderly men. Traditional Chinese medicine (TCM), with its multi-target action characteristics, has shown unique advantages in improving clinical symptoms and delaying disease progression. This paper focuses on the current application status of network pharmacology in the field of TCM treatment for BPH, a research method widely used to reveal the internal action mechanisms of TCM intervention in BPH. Taking TCM compound prescriptions such as Wuling San and Erzhi Wan as examples, relevant studies have shown that their therapeutic effects are often achieved through an integrated regulatory mechanism of “multi-component-multi-target-multi-pathway”. However, current research still faces the problem of numerous target predictions but insufficient experimental verification, as well as a lack of systematic evaluation of research quality. Therefore, it is necessary to further carry out in-depth basic experiments and clinical studies to fully validate the potential mechanisms predicted by network pharmacology, while introducing tools such as SYRCLE, ROBIS, and AMSTAR to enhance the reliability of research conclusions.